Merck & Co., Inc. (MRK) is seeing a flurry of interest, with the stock gaining attention for
dividend yields,
insider buying, and being among the most purchased by insiders recently. However, weak forecasts for 2025 and some downgrades by key analysts like Deutsche Bank, pointing out to potential lifecycle end issues for their flagship product
Keytruda, have taken a toll, causing the
stock to drop significantly. The halt on Gardasil vaccine shipments in China further eroded the 2025 outlook. Adding to the
volatility are investor class action alerts reminding shareholders about a lead plaintiff deadline. Despite these setbacks, several consider MRK a sound
investment, scoring well among high dividend stocks, drug stocks, and low volatility stocks.
Jim Cramer highlights the strength in MRK fundamentals, despite the stock trading around 52-week lows, and
billionaire investors like Premiere Watsa and D.E. Shaw have also shown a bullish stance. While MRK stands out as a great value in Dow and blue chip stocks, its position among Robinhood's most popular remains strong. With Q4 profits and forecasts falling short, critics argue whether it’s time to buy, hold or sell.
Merck Stocks MRK News Analytics from Mon, 04 Nov 2024 08:00:00 GMT to Sat, 22 Feb 2025 17:38:59 GMT -
Rating -2
- Innovation 2
- Information 5
- Rumor -6
